Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Geomerics Update

26 Mar 2012 07:00

RNS Number : 9988Z
Angle PLC
26 March 2012
ย 

๏ปฟ

For immediate release

26 March 2012

ย 

ANGLE plc

ย 

("ANGLE" or the "Company")

ย 

GEOMERICS EXPANDS PRODUCT RANGE AND SALES

ย 

ย 

ANGLE plc (AIM: AGL), the technology commercialisation company, is pleased to announce positive progress in new products, sales and market recognition at its 33%-owned portfolio company Geomerics, which specialises in computer games middleware.

ย 

At the recent Game Developers Conference (GDC 2012) in San Francisco, Geomerics announced the development of new products for mobile devices and for Nintendo's new Wiiโ„ข U console. These new products significantly expand the addressable market for Geomerics products.

ย 

The company demonstrated a range of new technologies aimed at rounding out the Enlighten offering and getting 'next gen ready'. In partnership with ARM, they showcased Enlighten running smoothly on a Mali-based Samsung Galaxy Tab 7.7 tablet on the expo floor. This is an expansion of Geomerics' product capability and Enlighten, via ARM CPU, now supports a wide range of mobile devices including the iOS-based iPad and iPhone, Android devices and PlayStationยฎ Vita, offering new sales opportunities.

ย 

Geomerics also announced its new product capability for Nintendo's new Wiiโ„ข U console, the successor to the highly successful Wiiโ„ข adding to its capability on the PC, PS3 and Xbox360. Geomerics also displayed on the NVIDIA and Intel booths at GDC 2012, reaffirming their commitment to high-end gaming experiences on the PC and console.

ย 

Geomerics sales continue to strengthen. Since GDC 2012 finished on 9th March, Geomerics has already been notified of four new sales for major new games, three of which are to entirely new customers, and its pipeline of prospective customers is steadily increasing.

ย 

Finally, there has been further market recognition for Geomerics' Enlighten with a BAFTA award being won by a computer game incorporating the Enlighten lighting solution.

ย 

The British Academy of Film and Television Arts (BAFTA) 2011 GAME Award has been awarded to Battlefield 3, an Electronic Arts game incorporating Enlighten.ย The GAME Award recognises the best game of the year, and is the only category at the British Academy Video Games Awards to be voted for by the general public.

ย 

Battlefield 3 is the fastest selling Electronic Arts game ever, selling more than 5 million units in its first week of release. Enlighten is the only real-time global illumination solution available for computer games, enabling the lighting to be realistically calculated in real-time as the player interacts with the game environment and other players. As a result, Enlighten provides a much more realistic player experience.

ย 

The reviews of Battlefield 3 have frequently singled out the lighting. For example The Guardian reported "Visually Battlefield 3 is a marvel of beautiful lighting effects" and GameSpy in its review said "Once they see the light - they'll understand what a special game Battlefield 3 is". The quality of the lighting and graphics in general has been a major contributor to the success of the game.

ย 

In a first time win at the BAFTA awards for the Battlefield franchise, it beat titles including FIFA 12, The Elder Scrolls V: Skyrim and Batman: Arkham City. Also, for the first time Battlefield beat the long-standing favourite Call of Duty, which has dominated the GAME Award for the past three years.

ย 

ย 

Gary Lewis, Chief Executive of Geomerics, commented:

"The BAFTA award for Battlefield 3 is an excellent further endorsement of the success of the game. We are pleased with ongoing adoption of the Enlighten technology in major new games. 2012 looks like being a great year for us and the expansion into mobile computing offers substantial growth potential for the future."

ย 

ย 

Andrew Newland, Chief Executive of ANGLE commented:

"We are delighted by Geomerics' ongoing success and believe the company is positioned well for the future."

ย 

ย 

ย 

ย 

ย 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

ย 

Cenkos Securities

Stephen Keys, Adrian Hargrave (Nominated adviser)

Andy Roberts (Sales)

ย 

020 7397 8900

Buchanan

Mark Court, Sophie Cowles

ย 

020 7466 5000

Scott Harris

Stephen Scott, Harry Dee

0207 653 0030

ย 

ย 

ย 

This information is provided by RNS
The company news service from the London Stock Exchange
ย 
END
ย 
ย 
MSCQXLFLLXFFBBL
Date   Source Headline
28th Jul 20227:00 amRNSNovel insight into metastasis in NSCLC patients
20th Jul 20222:33 pmRNSHolding(s) in Company
20th Jul 20227:00 amRNSNEW STUDY OF PARSORTIX SYSTEM IN NSCLC
19th Jul 202210:00 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSResults of Capital Raise
14th Jul 20225:24 pmRNSRetail Offer via PrimaryBid
14th Jul 20225:23 pmRNSProposed Placing and Retail Offer
8th Jul 20225:30 pmRNSIssue of Equity
29th Jun 20224:35 pmRNSResult of 2022 Annual General Meeting
27th Jun 20227:00 amRNSSpread of breast cancer accelerates during sleep
23rd Jun 20226:24 pmRNSIssue of Equity
22nd Jun 20227:00 amRNSSecured contract from pharma services customer
16th Jun 20227:00 amRNSPredicting immunotherapy response in SCLC
14th Jun 20227:00 amRNSPotential role of invasive cellular protrusions
30th May 20227:00 amRNSPartnership with major United States urology group
27th May 20227:00 amRNSMolecular characterisation of CTCs
25th May 20224:35 pmRNSPrice Monitoring Extension
25th May 202212:30 pmRNSANGLE receives FDA clearance for Parsortix
20th May 20227:00 amRNSProstate Cancer UK funds new study using Parsortix
28th Apr 20227:00 amRNSPreliminary Results
20th Apr 20227:00 amRNSNotice of Preliminary Results and Webcast
14th Apr 20227:00 amRNSPoster on Parsortix system presented at AACR 2022
1st Apr 20227:00 amRNSIdentifying drug targets in cancer metastasis
29th Mar 20227:00 amRNSRapid information on patient response to therapies
25th Mar 20227:00 amRNSIdentifying therapeutic targets in TNBC patients
15th Mar 20227:00 amRNSUpdate on laboratory accreditation
9th Mar 20224:41 pmRNSSecond Price Monitoring Extn
9th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20226:29 pmRNSHolding(s) in Company
18th Feb 20225:13 pmRNSIssue of Equity
21st Jan 20227:00 amRNSPotential in immunotherapy treatment selection
17th Jan 20227:00 amRNSConcordance of Parsortix with tissue biopsy
13th Jan 20227:00 amRNSUpdate on lab accreditation and ovarian study
10th Jan 20227:00 amRNSInsight into drug resistance in NSCLC
22nd Dec 20216:29 pmRNSIssue of Equity
1st Dec 20216:11 pmRNSIssue of Equity
1st Dec 20217:00 amRNSParsortix in RNA analysis of CTCs as tool in NSCLC
26th Nov 20215:33 pmRNSIssue of Equity
17th Nov 202110:32 amRNSIssue of Equity
15th Nov 20217:00 amRNSIssue of LTIP Options and Share Options
15th Nov 20217:00 amRNSAppointment of Chief Medical Officer
12th Nov 20215:51 pmRNSIssue of Equity
12th Nov 20217:00 amRNSParticipation at Jefferies healthcare conference
11th Nov 20217:00 amRNSParsortix system showcased at NCRI Festival
10th Nov 20215:40 pmRNSIssue of Equity
2nd Nov 20217:00 amRNSChange of Adviser
21st Oct 20215:25 pmRNSIssue of Equity
15th Oct 20215:45 pmRNSIssue of Equity
30th Sep 20214:02 pmRNSIssue of Equity
30th Sep 20217:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.